Search

Search Constraints

You searched for: Author/Creator Shinde, Anil

Search Results

2. 0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects. (12th April 2019)

3. 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates. (12th April 2019)

7. Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study. Issue 1 (1st June 2022)

8. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders. (June 2021)

10. P1‐397: SUVN‐G3031: A NOVEL AND POTENT HISTAMINE H3 RECEPTOR ANTAGONIST FOR POTENTIAL TREATMENT OF COGNITIVE DEFICITS. (1st July 2014)